Inventiva S.A. (IVA)
| Market Cap | 1.05B |
| Revenue (ttm) | 7.94M |
| Net Income (ttm) | -415.80M |
| Shares Out | 207.71M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,957 |
| Open | 5.13 |
| Previous Close | 5.13 |
| Day's Range | 5.03 - 5.13 |
| 52-Week Range | 2.85 - 7.98 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 16.20 (+220.79%) |
| Earnings Date | Mar 30, 2026 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is $16.2, which is an increase of 220.79% from the latest price.
News
Inventiva (IVA) Enhances Leadership Team with New Appointments
Inventiva (IVA) Enhances Leadership Team with New Appointments
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization. Axel-Sven Malkome...
New Options Listings for Inventiva SA (IVA) Set for April 15
New Options Listings for Inventiva SA (IVA) Set for April 15
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...
Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial Stability Amidst Challenges
Full Year 2025 Inventiva SA Earnings Call Transcript
Full Year 2025 Inventiva SA Earnings Call Transcript
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre-market after mixed Q4 results and lower sales guidance. Other stocks also ... Full story available ...
Inventiva Earnings Call Transcript: Q4 2025
Inventiva completed NATiV3 phase III enrollment for lanifibranor in MASH, expects top-line data in Q4 2026, and is well-funded through key milestones. Strategic focus, leadership expansion, and divestment of odiparcil position the company for regulatory and commercial readiness.
Inventiva reports 2025 full year results and provides a business update
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva Transcript: Barclays 28th Annual Global Healthcare Conference
Lanifibranor's Phase III trial for MASH is well-powered and builds on strong Phase IIb results, targeting F2/F3 patients with a favorable safety profile and differentiated market positioning. The company plans independent commercialization, with a cash runway through Q3 2027.
Inventiva Transcript: Leerink Global Healthcare Conference 2026
Lanifibranor's phase 3 program for MASH is on track for pivotal data in late 2024, with a focus on F2/F3 patients and a robust safety profile. Regulatory and commercial strategies are well-defined, with plans for accelerated approval, an F4 outcomes study, and patent protection through 2041.
Inventiva Transcript: TD Cowen 46th Annual Health Care Conference
NATiV3 phase III trial aims for a strong dual endpoint in F2/F3 NASH, with conservative powering and a focus on safety and tolerability. Commercial strategy targets both diabetic and non-diabetic populations, with future plans for F4/cACLD outcome studies and combination therapies.
Inventiva reports preliminary 2025¹ fiscal year financial results
Daix (France), New York City (New York, United States) , February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focus...
Inventiva Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Lanifibranor's phase III trial in MASH is fully enrolled, with top-line data expected in the second half of the year. The company is well-capitalized, targeting a large and growing market, and is positioned for both independent launch and strategic partnerships, with a focus on diabetic F2/F3 patients.
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the develop...
Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, which is on the verge of entering the fast-grow...
Inventiva Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant transformation and funding have positioned the company to advance lanifibranor, a pan-PPAR agonist for MASH, through a fully enrolled phase III trial with data expected later this year. Strategic preparations for commercialization and a robust cash runway support a potential 2028 launch.
Inventiva Transcript: Piper Sandler 37th Annual Healthcare Conference
A strengthened balance sheet and experienced leadership position the company for a pivotal 2026, with the Phase III NATiV3 trial for lanifibranor in MASH set to read out in the second half of next year. The study's robust design, market positioning, and operational readiness support a strong commercial launch strategy.
Inventiva reports 2025 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focus...
Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse...